ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2026
Galen vein malformation-intrauterine treatment.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVein of Galen malformation (VOGM) is a rare and severe congenital arteriovenous malformation. Its therapeutic results are complex and often catastrophic, making its treatment a true challenge. HISTORICAL
backgroundVOGM is characterized by the persistence of direct arteriovenous communications between the choroidal feeding arteries and the embryonic vein, known as the median prosencephalic vein of Markowski. CLINICAL PRESENTATION, DIAGNOSIS, AND PATHOPHYSIOLOGY: The malformation develops between the 8th and 11th weeks of gestation. Diagnostic suspicion is usually made through fetal ultrasound after the 18th week of gestation or later. Fetal MRI complements the diagnosis. MANAGEMENT, PROGNOSIS, AND OUTCOMES: There are two groups of patients with VOGM: severe cases, with persistent high-flow arteriovenous shunts leading to multiorgan failure, and mild cases with a lower mortality rate and a more favorable outcome. The use of vascular parameters, based on the diameter of the falcine sinus measured by fetal MRI, can serve as a predictor of neonatal outcome and therapeutic choice. CASE REPORT: A 33-year-old primigravida presented with a fetus diagnosed with VOGM by fetal ultrasound at 32 weeks of gestation. An aneurysmal dilation of the Galen vein was observed, with a transverse falcine sinus measuring 10.5 mm. Aneurysm dilatation dimensions: 25 × 21 × 20 mm. Fetal MRI confirmed a falcine sinus width of 10.5 mm, indicating a 96% chance of poor outcome. Fetal embolization of the VOGM was performed, followed by postnatal treatment.
conclusionsIn this article, we review the main principles of VOGM management and present a case treated during pregnancy, illustrating a potential therapeutic strategy. We suggest that fetal embolization of VOGM, when appropriately indicated, may represent an emerging approach in the management of this severe condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.